Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 Apr 23

PMID 35454017

Authors

Daniela Drandi

Philippe Decruyenaere

Martina Ferrante

Fritz Offner

Jo Vandesompele

Simone Ferrero

Affiliations

Soon will be listed here.

Abstract

Waldenström Macroglobulinemia (WM) is an indolent lymphoplasmacytic lymphoma, characterized by the production of excess immunoglobulin M monoclonal protein. WM belongs to the spectrum of IgM gammopathies, ranging from asymptomatic IgM monoclonal gammopathy of undetermined significance (IgM-MGUS), through IgM-related disorders and asymptomatic WM to symptomatic WM. In recent years, its complex genomic and transcriptomic landscape has been extensively explored, hereby elucidating the biological mechanisms underlying disease onset, progression and therapy response. An increasing number of mutations, cytogenetic abnormalities, and molecular signatures have been described that have diagnostic, phenotype defining or prognostic implications. Moreover, cell-free nucleic acid biomarkers are increasingly being investigated, benefiting the patient in a minimally invasive way. This review aims to provide an extensive overview of molecular biomarkers in WM and IgM-MGUS, considering current shortcomings, as well as potential future applications in a precision medicine approach.

Citing Articles

Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS).

Trojani A, Beghini A, Bossi L, Stefanucci M, Palumbo C, Greco A Cancer Med. 2024; 13(24):e70525.

PMID: 39711167 PMC: 11664121. DOI: 10.1002/cam4.70525.

The performance and applied value of F-FDG PET/CT imaging in Waldenstrom macroglobulinemia.

Pan B, Zhu X, Xie Q Am J Nucl Med Mol Imaging. 2023; 13(5):217-224.

PMID: 38023819 PMC: 10656628.

Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia.

Cholujova D, Beke G, Hunter Z, Hideshima T, Flores L, Zeleznikova T Int J Cancer. 2022; 152(9):1947-1963.

PMID: 36533670 PMC: 9992277. DOI: 10.1002/ijc.34405.

Liquid Biopsy in Cancer: Focus on Lymphoproliferative Disorders.

Savino F, Rigali F, Giustini V, DAliberti D, Spinelli S, Piazza R Cancers (Basel). 2022; 14(21).

PMID: 36358796 PMC: 9654765. DOI: 10.3390/cancers14215378.

Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal.

Rios-Tamayo R, Paiva B, Lahuerta J, Lopez J, Duarte R Cancers (Basel). 2022; 14(21).

PMID: 36358666 PMC: 9659226. DOI: 10.3390/cancers14215247.

References

Treon S, Xu L, Guerrera M, Jimenez C, Hunter Z, Liu X . Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020; 38(11):1198-1208. PMC: 7351339. DOI: 10.1200/JCO.19.02314. View

Jimenez C, Sebastian E, Chillon M, Giraldo P, Mariano Hernandez J, Escalante F . MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia. 2013; 27(8):1722-8. DOI: 10.1038/leu.2013.62. View

Trojani A, Di Camillo B, Bossi L, Leuzzi L, Greco A, Tedeschi A . Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells. Cancers (Basel). 2021; 13(8). PMC: 8070603. DOI: 10.3390/cancers13081837. View

Jalali S, Ansell S . Bone marrow microenvironment in Waldenstrom's Macroglobulinemia. Best Pract Res Clin Haematol. 2016; 29(2):148-155. DOI: 10.1016/j.beha.2016.08.016. View

Sekiguchi N, Nomoto J, Nagata A, Kiyota M, Fukuda I, Yamada K . Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion. Biomed Res Int. 2018; 2018:6728128. PMC: 6193339. DOI: 10.1155/2018/6728128. View

Jansson M, Lund A . MicroRNA and cancer. Mol Oncol. 2012; 6(6):590-610. PMC: 5528350. DOI: 10.1016/j.molonc.2012.09.006. View

Xu L, Hunter Z, Yang G, Zhou Y, Cao Y, Liu X . MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013; 121(11):2051-8. PMC: 3596964. DOI: 10.1182/blood-2012-09-454355. View

Hunter Z, Xu L, Yang G, Zhou Y, Liu X, Cao Y . The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2013; 123(11):1637-46. DOI: 10.1182/blood-2013-09-525808. View

Trojani A, Greco A, Tedeschi A, Lodola M, Di Camillo B, Ricci F . Microarray demonstrates different gene expression profiling signatures between Waldenström macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma Leuk. 2013; 13(2):208-10. DOI: 10.1016/j.clml.2013.02.012. View

10.

Morra E, Cesana C, Klersy C, Barbarano L, Miqueleiz S, Varettoni M . Prognostic factors for transformation in asymptomatic immunoglobulin m monoclonal gammopathies. Clin Lymphoma. 2005; 5(4):265-9. DOI: 10.3816/clm.2005.n.013. View

11.

Esteller M . Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer. 2006; 94(2):179-83. PMC: 2361113. DOI: 10.1038/sj.bjc.6602918. View

12.

Klein U, Tu Y, Stolovitzky G, Mattioli M, Cattoretti G, Husson H . Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001; 194(11):1625-38. PMC: 2193527. DOI: 10.1084/jem.194.11.1625. View

13.

Schop R, Van Wier S, Xu R, Ghobrial I, Ahmann G, Greipp P . 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet. 2006; 169(2):150-3. DOI: 10.1016/j.cancergencyto.2006.04.009. View

14.

Eis P, Tam W, Sun L, Chadburn A, Li Z, Gomez M . Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005; 102(10):3627-32. PMC: 552785. DOI: 10.1073/pnas.0500613102. View

15.

Jimenez C, Prieto-Conde M, Garcia-Alvarez M, Alcoceba M, Escalante F, Chillon M . Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study. Ann Hematol. 2018; 97(3):475-484. DOI: 10.1007/s00277-017-3207-3. View

16.

Mori N, Ohwashi M, Yoshinaga K, Mitsuhashi K, Tanaka N, Teramura M . L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma. PLoS One. 2013; 8(11):e80088. PMC: 3818242. DOI: 10.1371/journal.pone.0080088. View

17.

Chen L, Keddie S, Lunn M, Bomsztyk J, Vitsaras E, Gupta R . IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness. Br J Haematol. 2019; 188(4):511-515. DOI: 10.1111/bjh.16210. View

18.

Milanesi S, Locati M, Borroni E . Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom's Macroglobulinemia. Int J Mol Sci. 2020; 21(16). PMC: 7460815. DOI: 10.3390/ijms21165696. View

19.

Chang H, Qi C, Trieu Y, Jiang A, Young K, Chesney A . Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study. Clin Lymphoma Myeloma. 2009; 9(1):36-8. DOI: 10.3816/CLM.2009.n.008. View

20.

Braggio E, Philipsborn C, Novak A, Hodge L, Ansell S, Fonseca R . Molecular pathogenesis of Waldenstrom's macroglobulinemia. Haematologica. 2012; 97(9):1281-90. PMC: 3436227. DOI: 10.3324/haematol.2012.068478. View